Live measles vaccine expressing the secreted form of the west nile virus envelope glycoprotein protects against west nile virus encephalitis

Journal of Infectious Diseases

Volumn 191, Issue 2, 2005, Pages 207-214

  Desprès, Philippe ^a,b   Combredet, Chantal ^a   Frenkiel, Marie Pascale ^a   Lorin, Clarisse ^a   Brahic, Michel ^a   Tangy, Frédéric ^a  

^a INSTITUT PASTEUR   (France)

^b U Intrac Moleculaires F   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MEASLES VACCINE; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; HETEROLOGOUS EXPRESSION; INOCULATION; MEASLES VIRUS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; VIRUS ATTENUATION; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; VIRUS RECOMBINANT; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; ENCEPHALITIS; MEASLES VACCINE; MICE; MICE, INBRED BALB C; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS;

EID: 11844254477     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426824     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention. Global measles control and regional elimination, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:1124-30.
2. Griffin D. Measles virus. In: Knipe D, Howley P, eds. Fields virology. 4th ed. Vol. 2. Philadelphia: Lippincott-Raven Publishers, 2001:1401-41.
3. Hilleman M. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001; 20:651-65.
4. + T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10:411-6.
5. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14:5773-84.
6. Radecke F, Billeter M. Reverse genetics meets the nonsegmented negative-strand RNA viruses. Rev Med Virol 1997; 7:49-63.
7. Spielhofer P, Bachi T, Fehr T, et al. Chimeric measles viruses with a foreign envelope. J Virol 1998; 72:2150-9.
8. Singh M, Billeter M. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 1999; 80:101-6.
9. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 1999; 73:4823-8.
10. Wang Z, Hangartner T, Cornu L, et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 2001; 19:2329-36.
11. Lorin C, Mollet L, Delebecque F, et al. A single injection of recombinant measles vaccines expressing HIV-1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78:146-57.
12. Combredet C, Labrousse-Najburg V, Mollet L, et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003; 77:11546-54.
13. Brinton MA. The molecular biology of West Nile virus: a new invader of the Western Hemisphere. Annu Rev Microbiol 2002; 56:371-402.
14. O'Leary D, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004;4:61-70.
15. Deubel V, Fiette L, Gounon P, et al. Variations in biological features of West Nile virus. Ann NY Acad Sci 2001; 951:195-206.
16. Mashimo T, Lucas M, Simon-Chazottes D, et al. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci USA 2002; 99:11311-6.
17. Ceccaldi PE, Lucas M, Desprès P. New insights on the neuropathogenicity of West Nile virus. FEMS Microbiol Lett 2004; 233:1-6.
18. Charrel R, Brault A, Gallian P, et al. Evolutionary relationship between Old World West Nile virus strains: evidence for viral gene flow between Africa, the Middle East, and Europe. Virology 2003; 315:381-8.
19. Desprès P, Frenkiel M-P, Deubel V. Difference between cell membrane fusion activities of two dengue type-1 isolates reflects modifications of viral structure. Virology 1993; 196:209-19.
20. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993; 67:4822-30.
21. Schneider H, Kaelin K, Billeter MA. Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology 1997; 227:314-22.
22. Parks CL, Lerch RA, Walpita P, Sidhu MS, Udem SA. Enhanced measles virus cDNA rescue and gene expression after heat shock. J Virol 1999; 73:3560-6.
23. Desprès P, Griffin JW, Griffin DE. Antiviral activity of alpha interferon in Sindbis virus-infected cells is restored by anti-E2 monoclonal antibody treatment. J Virol 1995; 69:7345-8.
24. Lucas M, Mashimo T, Frenkiel M-P, et al. Infection of mouse neurons by West Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b protein. Immunol Cell Biol 2003; 81:230-6.
25. Davis BS, Chang B, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunsorbent assays. J Virol 2001; 75:4040-7.
26. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E. Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 2001; 167:5273-7.
27. Beasley D, Barrett A. Identification of neutralizing epitopes within the structural domain III of the West Nile virus envelope protein. J Virol 2002; 76:13097-100.
28. Haley M, Retter AS, Fowler D, Gea-Banacloche J, O'Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis 2003; 37:88-90.
29. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188:5-12.
30. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578-86.
31. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003; 188:1-4.
32. Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998; 72:7420-7.
33. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-21.
34. Lobigs M, Müllbacher A, Wang Y, Pavy M, Lee E. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J Gen Virol 2003; 84:567-72.
35. Beasley D, Davis C, Guzman H, et al. Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States. Virology 2003; 309:190-5.
36. Monath T. Prospects for development of a vaccine against the West Nile virus. Ann NY Acad Sci 2001; 951:1-12.
37. Monath TP, Arroyo J, Guirakhoo F. West Nile virus vaccine. Curr Drug Targets Infect Disord 2001; 1:37-50.
38. Petersen LR, Marfin AA, Gubler DJ. West Nile virus. JAMA 2003; 290: 524-8.
39. Lobigs M, Pavy M, Hall R. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 2003; 21:1572-9.
40. Putnak R, Porter K, Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res 2003; 61:445-68.
41. Arroyo J, Miller CA, Catalan J, Monath TP. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med 2001; 7:350-4.
42. Pletnev AG, St. Claire M, Elkin R, Speicher J, Murphy BR, Chanock RM. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect monkeys from West Nile virus. Virology 2003; 314:190-5.
43. Tesh R, Arroyo J, Travassos da Rosa A, Guzman H, Xiao S, Monath T. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002; 8:1392-7.
44. Ratterree M, Gutierrez R, Travassos da Rosa A, et al. Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 2004; 189:669-76.
45. Seligman S, Gould E. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363:2073-5.
46. Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 2003; 61:469-509.
47. Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to school-children: a randomized trial. Lancet 2000; 355:798-803.
48. Sepulveda-Amor J, Valdespino-Gomez JL, Garcia-Garcia ML, et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20:2790-5.
49. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26.
50. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003; 21:3398-405.
51. Halevy M, Akov Y, Ben-Nathan D, Kobiler D, Lachmi B, Lustig S. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenidty in immunocompetent and SCID mice. Arch Virol 1994; 137:355-70.
52. Engle M, Diamond M. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003; 77:12941-9.
53. Diamond M, Sitati E, Friend L, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003; 198:1853-62.
54. Isa M, Martinez L, Giordano M, Passeggi C, de Wolff M, Nates S. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin Diagn Lab Immunol 2002; 9:693-7.
55. + T cells in control of West Nile virus infection. J Virol 2004; 78:8312-21.